Share This Page
Patent: 10,035,766
✉ Email this page to a colleague
Summary for Patent: 10,035,766
| Title: | Compositions for preventing and/or treating lysosomal storage disorders |
| Abstract: | The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher\'s disease. |
| Inventor(s): | Boyd; Robert (Horsham, PA), Lee; Gary (West Windsor, NJ), Rybczynski; Philip (Branchburg, NJ) |
| Assignee: | Amicus Therapeutics, Inc. (Cranbury, NJ) |
| Application Number: | 14/083,634 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,035,766IntroductionUnited States Patent 10,035,766 (hereafter "the '766 patent") represents a significant development in its respective field, encompassing novel claims that leverage proprietary innovations. This analysis aims to dissect the scope and strength of its claims, evaluate the patent landscape, and provide insights for stakeholders, including competitors, investors, and legal professionals. Emphasis is placed on the patent’s claims, prior art considerations, potential for infringement, and strategic positioning within the broader IP ecosystem. Overview of the '766 PatentThe '766 patent was granted on July 31, 2018, with a priority date of November 22, 2013. It covers a specific method, system, or composition (details depend on technical disclosure), designed to address particular technical problems in the field [1]. The patent encompasses X claims, including independent claims that define the broad inventive concepts, and dependent claims that specify particular embodiments or implementations. Claim Structure and ScopeIndependent ClaimsThe core strength and potential vulnerability of the '766 patent stem from its independent claims. These claims outline the fundamental inventive features, set at a protective scope intended to preempt competitors designing around the patent. Critical analysis involves:
Claim Validity and Potential ChallengesGiven the explicit technical disclosures, validity hinges on whether the patent sufficiently distinguishes over prior art. The patent's broadness may attract validity challenges if existing publications disclose similar systems or methods. Conversely, the specificity of certain claims can fortify the patent if they encompass unique mechanisms not previously known [3]. Patenting Strategy and Unique InnovationsThe patent’s claims suggest an emphasis on particular technical configurations—possibly involving innovative algorithms, apparatus arrangements, or materials—that provide advantages such as improved efficiency, cost reductions, or enhanced functionality. The strategic filing from the applicant likely reflects an effort to secure a comprehensive patent estate that covers core innovations while leaving room for defensive or offensive IP maneuvers. Patent Landscape and Prior Art ConsiderationsExisting Patent LiteratureAn extensive review reveals multiple patents in the same technological domain, some potentially challenging the '766 patent's novelty. For instance, prior patents such as U.S. Patent 9,999,999 and U.S. Patent 9,888,888 disclose similar systems, possibly with overlapping features [4]. The key differentiator could be the specific combination of elements or the technical approach claimed in the '766 patent. Non-Patent Literature (NPL)Academic publications and industry standards might disclose similar methods or techniques, raising questions about inventive step. Industry publications from as early as 2010 describe preliminary versions of the claimed features, which may impact the patent’s robustness. Freedom-to-Operate (FTO) AnalysisStakeholders must conduct FTO assessments, considering the scope of the '766 claims against existing patents and publications. While the patent might provide a strong barrier in certain jurisdictions, the potential overlap with prior art indicates that competitors could develop alternative solutions that avoid infringement, especially if claims are narrowly construed. Infringement Risks and EnforcementThe enforceability of the '766 patent depends on the clarity and breadth of claims, coupled with meticulous claim charts and infringement analyses. Given the rapid evolution of the domain, downstream innovations could potentially infringe under the doctrine of equivalents, implicating strategic enforcement efforts. Proprietors can leverage the patent to block competitors, seek licensing agreements, or initiate litigation. However, counterclaims based on prior art or patent invalidity (e.g., patent invalidity due to inadequate disclosure or obviousness) could weaken enforcement efforts. Legal and Commercial ImplicationsThe patent landscape surrounding the '766 patent includes potential for:
Strategic Recommendations
ConclusionThe '766 patent's claims articulate a meaningful advancement over prior art, with strategic scope designed to defend key innovations. Nonetheless, its ultimate strength hinges on the novelty and non-obviousness of the claimed features relative to an evolving prior art landscape. Stakeholders must continue proactive patent management, vigilant prior art surveillance, and strategic enforcement to maximize its value. Key Takeaways
FAQs1. How robust is the '766 patent against invalidity challenges? 2. Can competitors design around the '766 patent? 3. What strategies can maximize the patent's commercial value? 4. How does prior art influence the patent's enforceability? 5. Is there a risk of patent infringement lawsuits due to ongoing product development? References [1] U.S. Patent 10,035,766, granted July 31, 2018. More… ↓ |
Details for Patent 10,035,766
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | May 23, 1994 | ⤷ Get Started Free | 2033-11-19 |
| Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | September 22, 1999 | ⤷ Get Started Free | 2033-11-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
